A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma,
according to the results of an
early -
phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma
clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the
Clinical Lymphoma
Clinical Lymphoma Program.